HU-210
From Wikipedia, the free encyclopedia
 |
|
|
HU-210
|
|
| Systematic (IUPAC) name | |
| (6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C25H38O3 |
| Mol. mass | 386.567 g/mol |
| Synonyms | 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
HU-210 is a synthetic cannabinoid that was synthesized around 1988 in the group of Prof. Raphael Mechoulam at the Hebrew University. HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an extended duration of action.[1] HU-210 is the (-)-1,1-dimethylheptyl analog of 11-hydroxy-Δ8-tetrahydrocannabinol, in some references it is called 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol. The abbreviation HU stands for Hebrew University.
Per a 2005 article in the Journal Of Clinical Investigation, HU-210 with daily high doses over a few weeks stimulates neural growth in rats' hippocampus region, the opposite effect of drugs like alcohol, nicotine, heroin, and cocaine. It was also indicated by this increased neural growth to entail antianxiety and antidepressant effects.[2]
HU-210, alongside WIN 55,212-2 and JWH-133, is implicated in preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This anti-inflammatory action is induced through the agonization of cannabinoid receptors which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.[3]
[edit] References
- ^ Devane WA, Breuer A, Sheskin T, Järbe TU, Eisen MS, Mechoulam R (1992). "A novel probe for the cannabinoid receptor". J. Med. Chem. 35 (11): 2065–9. doi:. PMID 1317925.
- ^ Jiang W, Zhang Y, Xiao L, et al (2005). "Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects". J. Clin. Invest. 115 (11): 3104–16. doi:. PMID 16224541.
- ^ Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (2005). "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation". J. Neurosci. 25 (8): 1904–13. doi:. PMID 15728830.
[edit] External links
|
|||||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
